NovaVive has an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with 5 USDA-approved products. One of these products – Amplimune® – is approved for the treatment of scours in neonatal calves, as an alternative to antibiotics. Recent data from a University of Minnesota research study demonstrated that shipped calves were 46% less likely to require treatment for pneumonia if treated with one dose of Amplimune prior to shipping.